MAXY Key Stats
- Maxygen (MAXY) Narrows Q1 Loss Street Insider May 3
- Maxygen Reports First Quarter 2013 Financial Results Business Wire May 3
- MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, F... May 3
- MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, F... Mar 12
- Maxygen (MAXY) Narrows Q4 Loss to 6c/Share Street Insider Mar 12
- Maxygen Reports Fourth Quarter and Year End 2012 Financial Results Business Wire Mar 12
- Maxygen Announces Tax Treatment of 2012 Cash Distribution noodls Jan 30
- Maxygen Announces Tax Treatment of 2012 Cash Distribution Business Wire Jan 29
- MAXYGEN INC Files SEC form 8-K, Other Events Nov 16
- High-Performing Biotech Fund To Add Six Stocks, Drop Maxygen, Progenics Nov 12
MAXY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Maxygen is up 129.4% over the last year vs S&P 500 Total Return up 28.68%, ARCA biopharma down 3.41%, and Sangamo BioSciences up 68.17%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for MAXY
Pro Report PDF for MAXY
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download MAXY Pro Report PDF
Pro Strategies Featuring MAXY
Did Maxygen make it into our Pro Portfolio Strategies?